Yu Wei
Shanghai Key Laboratory Of Regulatory Biology
Shanghai, China
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Engineering a drug-inducible pyroptosis platform enables precise tumor suppression in colorectal cancer.
Journal: Synthetic and systems biotechnology
Published: August 04, 2025
Optogenetics in medicine: innovations and therapeutic applications.
Journal: Current opinion in biotechnology
Published: December 01, 2024
Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.
Journal: Cell reports. Medicine
Published: August 06, 2024
Corrigendum to "Long-term correction of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration" [Journal of Genetics and Genomics (2022) 49, 1114-1126].
Journal: Journal of genetics and genomics = Yi chuan xue bao
Published: June 09, 2024
Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus.
Journal: Research square
Published: April 22, 2024
From biology to the clinic - exploring liver metastasis in prostate cancer.
Journal: Nature reviews. Urology
Published: March 22, 2024
Combined SNPs sequencing and allele specific proteomics capture reveal functional causality underpinning the 2p25 prostate cancer susceptibility locus.
Journal: Nature communications
Published: February 09, 2024
Exploring plant-derived phytochrome chaperone proteins for light-switchable transcriptional regulation in mammals.
Journal: Nature communications
Published: January 04, 2024
Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer.
Journal: Med (New York, N.Y.)
Published: January 02, 2024
Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: December 22, 2023
Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.
Journal: BMC cancer
Published: December 15, 2023
Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer.
Journal: European urology oncology
Published: October 04, 2023
Last Updated: 09/26/2026